TERT Promoter Mutation Detection in Cell-Free Tumor-Derived DNA in Patients with IDH Wild-Type Glioblastomas: A Pilot Prospective Study

dc.contributor.authorJuratli, Tareq A.
dc.contributor.authorStasik, Sebastian
dc.contributor.authorZolal, Amir
dc.contributor.authorSchuster, Caroline
dc.contributor.authorRichter, Sven
dc.contributor.authorDaubner, Dirk
dc.contributor.authorJuratli, Mazen A.
dc.contributor.authorThowe, Rachel
dc.contributor.authorHennig, Silke
dc.contributor.authorMakina, Meriem
dc.contributor.authorMeinhardt, Matthias
dc.contributor.authorLautenschlaeger, Tim
dc.contributor.authorSchackert, Gabriele
dc.contributor.authorKrex, Dietmar
dc.contributor.authorThiede, Christian
dc.contributor.departmentRadiation Oncology, School of Medicineen_US
dc.date.accessioned2019-05-24T18:01:00Z
dc.date.available2019-05-24T18:01:00Z
dc.date.issued2018-11
dc.description.abstractPurpose: We conducted a pilot study to assess the feasibility and the potential implications of detecting TERT promoter (TERTp)–mutant cell-free tumor-derived DNA (tDNA) in the cerebrospinal fluid (CSF) and plasma of glioblastoma patients. Experimental Design: Matched CSF and plasma samples were collected in 60 patients with glial tumors. The CSF collection was obtained during surgery, before any surgical manipulation of the tumor. The extracted tDNA and corresponding tumor DNA samples were analyzed for TERTp and isocitrate dehydrogenase (IDH) hotspot mutations. In addition, the variant allele frequency (VAF) of TERTp mutation in the CSF-tDNA was correlated with tumor features and patients’ outcome. Results: Thirty-eight patients had TERTp-mutant/IDH wild-type glioblastomas. The matched TERTp mutation in the CSF-tDNA was successfully detected with 100% specificity (95% CI, 87.6–100%) and 92.1% sensitivity (95% CI, 78.6–98.3%) (n = 35/38). In contrast, the sensitivity in the plasma-tDNA was far lower [n = 3/38, 7.9% (95% CI, 1.6–21.4%)]. We concordantly observed a longer overall survival of patients with low VAF in the CSF-tDNA when compared with patients with high VAF, irrespective of using the lower quartile VAF [11.45%; 14.0 mo. (95% confidence interval, CI, 10.3–17.6) vs. 8.6 mo. (95% CI, 4.1–13.2), P = 0.035], the lower third VAF [13%; 15.4 mo. (95% CI, 11.6–19.2) vs. 8.3 mo. (95% CI, 2.3–14.4), P = 0.008], or the median VAF [20.3%; 14.0 mo. (95% CI, 9.2–18.7) vs. 8.6 mo. (95% CI, 7.5–9.8), P = 0.062] to dichotomize the patients. Conclusions: This pilot study highlights the value of CSF-tDNA for an accurate and reliable detection of TERTp mutations. Furthermore, our findings suggest that high TERTp mutation VAF levels in the CSF-tDNA may represent a suitable predictor of poor survival in glioblastoma patients. Further studies are needed to complement the findings of our exploratory analysis.en_US
dc.eprint.versionAuthor's manuscripten_US
dc.identifier.citationJuratli, T. A., Stasik, S., Zolal, A., Schuster, C., Richter, S., Daubner, D., … Thiede, C. (2018). TERT Promoter Mutation Detection in Cell-Free Tumor-Derived DNA in Patients with IDH Wild-Type Glioblastomas: A Pilot Prospective Study. Clinical Cancer Research, 24(21), 5282–5291. https://doi.org/10.1158/1078-0432.CCR-17-3717en_US
dc.identifier.urihttps://hdl.handle.net/1805/19466
dc.language.isoenen_US
dc.publisherAACRen_US
dc.relation.isversionof10.1158/1078-0432.CCR-17-3717en_US
dc.relation.journalClinical Cancer Researchen_US
dc.rightsPublisher Policyen_US
dc.sourceAuthoren_US
dc.subjectbrain tumoren_US
dc.subjectTERT promoteren_US
dc.subjectcerebrospinal fluiden_US
dc.titleTERT Promoter Mutation Detection in Cell-Free Tumor-Derived DNA in Patients with IDH Wild-Type Glioblastomas: A Pilot Prospective Studyen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Juratli_2018_TERT.pdf
Size:
1.46 MB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: